Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | CCNH | P51946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5014018 | 0.88 | HPGD (0.52) | KMT2ATSHRHPGDKDM4EMEN1 | |
| SCHEMBL12423131 | 0.82 | CCNT1 (0.66) | KMT2AL3MBTL1TSHRMEN1CCNT1 | |
| SCHEMBL5012763 | 0.80 | SMN1; SMN2 (0.59) | KMT2AL3MBTL1SMN1; SMN2TSHRHPGD | |
| SCHEMBL12423541 | 0.78 | IKBKB (0.58) | KMT2AMEN1CCNT1CDK1CCNB1 | |
| SCHEMBL3295635 | 0.78 | PKM (0.55) | KMT2AGLAPKML3MBTL1SMN1; SMN2 | |
| SCHEMBL18175986 | 0.76 | PKM (0.55) | PKML3MBTL1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL5014387 | 0.75 | ERN1 (0.47) | KMT2APKML3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL17689077 | 0.73 | HPGD (0.60) | KMT2AGLAPKML3MBTL1SMN1; SMN2 | |
| SCHEMBL3249195 | 0.73 | PKM (0.63) | KMT2APKML3MBTL1SMN1; SMN2HPGD | |
| SCHEMBL12423479 | 0.72 | CCNT1 (0.48) | CCNT1CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| CN-101124232-A | Nicotinic acetylcholine receptor ligands | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | CN | disclosed |
| EP-1831231-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065209-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNA2, CHRNB1 | KMT2A 1975/4885GLA 1818/4885PKM 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.